DelfaGLP-1 Atlas

Lead sponsor

Dasman Diabetes Institute

5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

5

Trials led

3

Active

735

Total enrollment

1

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 4
2
Not applicable
3

Trials by status

Not yet recruiting
1
Recruiting
2
Completed
1
Unknown
1

Trials led

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM PatientsBMI 18-45Ph 4Unknown315
LEAN-PREP—not applicableRecruiting232
TiTREBMI ≥27not applicableNot yet recruiting68
Tirzepatide Use in People With Obesity and Type 1 DiabetesBMI ≥27Ph 4Recruiting60
OTIDBMI ≥25not applicableCompleted60